Immutep Ltd operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Immutep Ltd with three other companies in this sector in AUSTRALIA : Idt Australia Limited. (2020 sales of 14.17 million Australian Dollars [US$10.80 million] ), Pharmaxis Ltd (12.55 million Australian Dollars [US$9.57 million] of which 56% was Mannitol), and Cellmid Limited (7.48 million Australian Dollars [US$5.70 million] of which 79% was Advangen Japan).

Sales Analysis. During the year ended June of 2020, sales at Immutep Ltd were A$13.94 million (US$10.62 million). This is an increase of 131.0% versus 2019, when the company's sales were A$6.03 million. Sales of Cancer Immunotherapy saw an increase of 143.7% in 2020, from A$5.64 million to A$13.74 million.